Single or double induction with 7 + 3 containing standard or high-dose daunorubicin for newly diagnosed AML: the randomized daunodouble trial by the study Alliance Leukemia

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023736%3A_____%2F25%3A00013722" target="_blank" >RIV/00023736:_____/25:00013722 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11120/25:43927555 RIV/65269705:_____/25:00081020 RIV/00064173:_____/25:43927555

Výsledek na webu

<a href="https://doi.org/10.1200/JCO.24.00235" target="_blank" >https://doi.org/10.1200/JCO.24.00235</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1200/JCO.24.00235" target="_blank" >10.1200/JCO.24.00235</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Single or double induction with 7 + 3 containing standard or high-dose daunorubicin for newly diagnosed AML: the randomized daunodouble trial by the study Alliance Leukemia

Popis výsledku v původním jazyce

To determine the optimal daunorubicin dose and number of 7 + 3 induction cycles in newly diagnosed AML, this randomized controlled trial compared a once daily dose of 60 mg/m2 with 90 mg/m2 daunorubicin in the first 7 + 3 induction and one versus two cycles of 7 + 3 induction. The use of 90 mg/m2 daunorubicin once daily in the context of classical 7 + 3 induction does not significantly improve early response and does not lead to higher remission rates or longer survival than 60 mg/m2 once daily. In patients with a good early response after first induction, a second induction has only a limited impact on RFS and does not result in an OS benefit.

Název v anglickém jazyce

Single or double induction with 7 + 3 containing standard or high-dose daunorubicin for newly diagnosed AML: the randomized daunodouble trial by the study Alliance Leukemia

Popis výsledku anglicky

To determine the optimal daunorubicin dose and number of 7 + 3 induction cycles in newly diagnosed AML, this randomized controlled trial compared a once daily dose of 60 mg/m2 with 90 mg/m2 daunorubicin in the first 7 + 3 induction and one versus two cycles of 7 + 3 induction. The use of 90 mg/m2 daunorubicin once daily in the context of classical 7 + 3 induction does not significantly improve early response and does not lead to higher remission rates or longer survival than 60 mg/m2 once daily. In patients with a good early response after first induction, a second induction has only a limited impact on RFS and does not result in an OS benefit.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30205 - Hematology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2025

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Journal of clinical oncology

ISSN

0732-183X

e-ISSN

—

Svazek periodika

43

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

12

Strana od-do

65-74

Kód UT WoS článku

001091456900051

EID výsledku v databázi Scopus

2-s2.0-85204701862